Key facts
- This page summarizes Annette North's Form 4 filing for Turning Point Therapeutics, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Feb 2022, 17:09.
Annette North - 09 Feb 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.
- Reporting relationship
- EVP & General Counsel
- Issuer ticker
- N/A
- Reported as of
- 09 Feb 2022
- Net transaction value
- -$24,285
- SEC form
- 4
- Accepted by SEC
- 11 Feb 2022, 17:09:14 UTC
- Prior SEC filing
- 31 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paolo Tombesi, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Annette North filed Form 4 for Turning Point Therapeutics, Inc. on 11 Feb 2022.
Change
- Previous filing in this sequence was filed on 31 Aug 2021.
- Current net transaction value: -$24,285.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TPTX
transaction
Common Stock
Sale
- Transaction value
- $24,285
- Shares
- -669
- Change %
- -5.4%
- Price
- $36.30
- Shares after
- 11,696
- Date
- 09 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
TPTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,283
- Change %
- +139%
- Price
- $0.000000
- Shares after
- 27,979
- Date
- 09 Feb 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TPTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +58,600
- Change %
- Price
- $0.000000
- Shares after
- 58,600
- Date
- 09 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 58,600
- Exercise price
- $37.68
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
Footnote F2
Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
Footnote F3
1/48th of the shares vest monthly following February 9, 2022.